<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="347aa0d3-ae81-ed7b-e063-6394a90ac68b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Nystatin and Triamcinolone Acetonide Cream, USP
 <br/>
Nystatin and Triamcinolone Acetonide Ointment, USP
</title>
   <effectiveTime value="20250506"/>
   <setId root="ea065dd4-dfd3-46a2-92de-8a0b49cb9455"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="829572556"/>
            <name>REMEDYREPACK INC.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="347aa4e7-96f4-ea6c-e063-6394a90a717a"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250506"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70518-1114" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Nystatin and Triamcinolone Acetonide</name>
                        <formCode code="C28944" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CREAM"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Nystatin and Triamcinolone Acetonide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="51672-1263" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5QB0T2IUN0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALUMINUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="230OU9XXE4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERYL MONOSTEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X045WJ989B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4T6H12BN9U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PETROLATUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="[USP'U]" value="100000"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="BDF1O1C72E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NYSTATIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="BDF1O1C72E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NYSTATIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F446C597KA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIAMCINOLONE ACETONIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="F446C597KA" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRIAMCINOLONE ACETONIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="CAL22UVI4M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 60</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="70518-1114-0" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180412"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA062364" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180412"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText>light yellow to buff color</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="2e800cb7-f2fd-ad1d-e063-6294a90a4685"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250219"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2e800cb7-f2fe-ad1d-e063-6294a90a4685"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Nystatin and Triamcinolone Acetonide Cream and Ointment for dermatologic use contain the antifungal agent nystatin and the synthetic corticosteroid triamcinolone acetonide.</paragraph>
                  <paragraph>Nystatin is a polyene antimycotic obtained from Streptomyces noursei. It is a yellow to light tan powder with a cereallike odor, very slightly soluble in water, and slightly to sparingly soluble in alcohol. Structural formula:</paragraph>
                  <table width="100%">
                     <col align="center" width="70%" valign="bottom"/>
                     <col align="left" width="30%" valign="bottom"/>
                     <tbody>
                        <tr styleCode="Botrule Toprule">
                           <td colspan="2">
                              <renderMultiMedia referencedObject="MM1"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td/>
                           <td>C
    
     <sub>47</sub>H
    
     <sub>75</sub>NO
    
     <sub>17</sub>MW = 926.13
   
    </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Triamcinolone acetonide is designated chemically as 9-fluoro-11β, 16α, 17, 21-tetrahydroxypregna-1, 4-diene-3, 20-dione cyclic 16, 17-acetal with acetone. The white to cream crystalline powder has a slight odor, is practically insoluble in water, and very soluble in alcohol. Structural formula:</paragraph>
                  <table width="100%">
                     <col align="center" width="70%" valign="bottom"/>
                     <col align="left" width="30%" valign="bottom"/>
                     <tbody>
                        <tr styleCode="Botrule Toprule">
                           <td colspan="2">
                              <renderMultiMedia referencedObject="MM2"/>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td/>
                           <td>C
    
     <sub>24</sub>H
    
     <sub>31</sub>FO
    
     <sub>6</sub>MW = 434.50
   
    </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Nystatin and Triamcinolone Acetonide Cream is a soft, smooth cream having a light yellow to buff color. Each gram provides 100,000 USP Nystatin units and 1 mg Triamcinolone Acetonide in an aqueous perfumed vanishing cream base with polysorbate-60, aluminum hydroxide, titanium dioxide, glyceryl monostearate, polyethylene glycol monostearate, simethicone emulsion, sorbic acid, propylene glycol, white petrolatum, polyoxyethylene fatty alcohol ether, methylparaben, propylparaben and sorbitol.</paragraph>
                  <paragraph>Each gram of Nystatin and Triamcinolone Acetonide Ointment provides 100,000 USP Nystatin units and 1 mg Triamcinolone Acetonide in an ointment base of mineral oil and white petrolatum.</paragraph>
               </text>
               <effectiveTime value="20250219"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="nystatin-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="nystatin-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2e800cb7-f2ff-ad1d-e063-6294a90a4685"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250219"/>
               <component>
                  <section>
                     <id root="2e800cb7-f300-ad1d-e063-6294a90a4685"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Nystatin</title>
                     <text>
                        <paragraph>Nystatin exerts its antifungal activity against a variety of pathogenic and nonpathogenic yeasts and fungi by binding to sterols in the cell membrane. The binding process renders the cell membrane incapable of functioning as a selective barrier. Nystatin provides specific anticandidal activity to
 
  <content styleCode="italics">Candida</content>(Monilia)
 
  <content styleCode="italics">albicans</content>and other Candida species, but is not active against bacteria, protozoa, trichomonads, or viruses.

 </paragraph>
                        <paragraph>Nystatin is not absorbed from intact skin or mucous membranes.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2e800cb7-f301-ad1d-e063-6294a90a4685"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Triamcinolone Acetonide</title>
                     <text>
                        <paragraph>Triamcinolone acetonide is primarily effective because of its anti-inflammatory, antipruritic and vasoconstrictive actions, characteristic of the topical corticosteroid class of drugs. The pharmacologic effects of the topical corticosteroids are well known; however, the mechanisms of their dermatologic actions are unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2e800cb7-f302-ad1d-e063-6294a90a4685"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics</title>
                     <text>
                        <paragraph>the extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings (see
 
  <content styleCode="bold">
                              <linkHtml href="#DA">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>).

 </paragraph>
                        <paragraph>Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (see
 
  <content styleCode="bold">
                              <linkHtml href="#DA">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>).

 </paragraph>
                        <paragraph>Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2e800cb7-f303-ad1d-e063-6294a90a4685"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Nystatin and Triamcinolone Acetonide</title>
                     <text>
                        <paragraph>During clinical studies of mild to severe manifestations of cutaneous candidiasis, patients treated with nystatin and triamcinolone acetonide showed a faster and more pronounced clearing of erythema and pruritus than patients treated with nystatin or triamcinolone acetonide alone.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2e800cb7-f304-ad1d-e063-6294a90a4685"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Nystatin and Triamcinolone Acetonide Cream and Ointment are indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.</paragraph>
               </text>
               <effectiveTime value="20250219"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2e800cb7-f305-ad1d-e063-6294a90a4685"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>These preparations are contraindicated in those patients with a history of hypersensitivity to any of their components.</paragraph>
               </text>
               <effectiveTime value="20250219"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2e800cb7-f306-ad1d-e063-6294a90a4685"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20250219"/>
               <component>
                  <section ID="GE">
                     <id root="2e800cb7-f307-ad1d-e063-6294a90a4685"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions that augment systemic absorption include application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings (see
 
  <content styleCode="bold">
                              <linkHtml href="#DA">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>).

 </paragraph>
                        <paragraph>Therefore, patients receiving a large dose of any potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of internal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, or substitute a less potent steroid.</paragraph>
                        <paragraph>Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.</paragraph>
                        <paragraph>Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see
 
  <content styleCode="bold">
                              <linkHtml href="#PU">PRECAUTIONS, Pediatric Use</linkHtml>
                           </content>).

 </paragraph>
                        <paragraph>If irritation or hypersensitivity develops with the combination nystatin and triamcinolone acetonide, treatment should be discontinued and appropriate therapy instituted.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2e800cb7-f308-ad1d-e063-6294a90a4685"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for the Patient</title>
                     <text>
                        <paragraph>Patients using this medication should receive the following information and instructions:</paragraph>
                        <list listType="ordered">
                           <item>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.</item>
                           <item>Patients should be advised not to use this medication for any disorder other than for which it was prescribed.</item>
                           <item>The treated skin area should not be bandaged or otherwise covered or wrapped as to be occluded (see
  
   <content styleCode="bold">
                                 <linkHtml href="#DA">DOSAGE AND ADMINISTRATION</linkHtml>
                              </content>).
 
  </item>
                           <item>Patients should report any signs of local adverse reactions.</item>
                           <item>When using this medication in the inguinal area, patients should be advised to apply the cream or ointment sparingly and to wear loose fitting clothing.</item>
                           <item>Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.</item>
                           <item>Patients should be advised on preventive measures to avoid reinfection.</item>
                        </list>
                        <paragraph>Repackaged By / Distributed By: RemedyRepack Inc.</paragraph>
                        <paragraph>625 Kolter Drive, Indiana, PA 15701</paragraph>
                        <paragraph>(724) 465-8762</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="LT">
                     <id root="2e800cb7-f309-ad1d-e063-6294a90a4685"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests</title>
                     <text>
                        <paragraph>If there is a lack of therapeutic response, appropriate microbiological studies (e.g. KOH smears and/or cultures) should be repeated to confirm the diagnosis and rule out other pathogens, before instituting another course of therapy.</paragraph>
                        <paragraph>A urinary free cortisol test and ACTH stimulation test may be helpful in evaluating hypothalamic-pituitary-adrenal (HPA) axis suppression due to corticosteroids.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2e800cb7-f30a-ad1d-e063-6294a90a4685"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, and Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term animal studies have not been performed to evaluate carcinogenic or mutagenic potential, or possible impairment of fertility in males or females.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2e800cb7-f30b-ad1d-e063-6294a90a4685"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy Category C</title>
                     <text>
                        <paragraph>There are no teratogenic studies with combined nystatin and triamcinolone acetonide. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Therefore, any topical corticosteroid preparation should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                        <paragraph>Topical preparations containing corticosteroids should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2e800cb7-f30c-ad1d-e063-6294a90a4685"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether any component of this preparation is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised during the use of this preparation by a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="PU">
                     <id root="2e800cb7-f30d-ad1d-e063-6294a90a4685"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>In clinical studies of a limited number of pediatric patients ranging from two months through 12 years, nystatin and triamcinolone acetonide cream formulation cleared or significantly ameliorated the disease state in most patients.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.</content>
                        </paragraph>
                        <paragraph>HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.</paragraph>
                        <paragraph>Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2e800cb7-f30e-ad1d-e063-6294a90a4685"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>A single case (approximately one percent of patients studied) of acneiform eruption occurred with use of combined nystatin and triamcinolone acetonide in clinical studies.</paragraph>
                  <paragraph>Nystatin is virtually nontoxic and nonsensitizing and is well tolerated by all age groups, even during prolonged use. Rarely, irritation may occur.</paragraph>
                  <paragraph>The following local adverse reactions are reported infrequently with topical corticosteroids (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, perioral secondary infection, skin atrophy, striae and miliaria.</paragraph>
               </text>
               <effectiveTime value="20250219"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2e800cb7-f30f-ad1d-e063-6294a90a4685"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see
 
  <content styleCode="bold">
                        <linkHtml href="#GE">PRECAUTIONS, General</linkHtml>
                     </content>); however, acute overdosage and serious adverse effects with dermatologic use are unlikely.

 </paragraph>
               </text>
               <effectiveTime value="20250219"/>
            </section>
         </component>
         <component>
            <section ID="DA">
               <id root="2e800cb7-f310-ad1d-e063-6294a90a4685"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Nystatin and Triamcinolone Acetonide Cream is usually applied to the affected areas twice daily in the morning and evening by gently and thoroughly massaging the preparation into the skin. The cream should be discontinued if symptoms persist after 25 days of therapy (see
 
  <content styleCode="bold">
                        <linkHtml href="#LT">PRECAUTIONS, Laboratory Tests</linkHtml>
                     </content>).

 </paragraph>
                  <paragraph>A thin film of Nystatin and Triamcinolone Acetonide Ointment is usually applied to the affected areas twice daily in the morning and evening. The preparation should be discontinued if symptoms persist after 25 days of therapy (see
 
  <content styleCode="bold">
                        <linkHtml href="#LT">PRECAUTIONS, Laboratory Tests</linkHtml>
                     </content>).

 </paragraph>
                  <paragraph>Nystatin and Triamcinolone Acetonide Cream and Ointment should not be used with occlusive dressings.</paragraph>
               </text>
               <effectiveTime value="20250219"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2e800cb7-f311-ad1d-e063-6294a90a4685"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Nystatin and Triamcinolone Acetonide Cream is supplied in 30 g tubes.</paragraph>
                  <paragraph/>
                  <paragraph>NDC: 70518-1114-00</paragraph>
                  <paragraph>PACKAGING: 1 in 1 CARTON, 30 g in 1 TUBE, TYPE 0</paragraph>
                  <paragraph/>
                  <paragraph>STORAGE</paragraph>
                  <paragraph>Store at 20°-25°C (68°-77°F)[see USP Controlled Room Temperature]. Avoid freezing.</paragraph>
                  <paragraph/>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250219"/>
            </section>
         </component>
         <component>
            <section ID="id_link_2e80180c-e145-f8dd-e063-6294a90adf4e">
               <id root="2e80180c-e144-f8dd-e063-6294a90adf4e"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
               </text>
               <effectiveTime value="20250219"/>
            </section>
         </component>
         <component>
            <section ID="id_link_347aa5c6-288b-f243-e063-6394a90ad756">
               <id root="347aa5c6-288a-f243-e063-6394a90ad756"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>DRUG: Nystatin and Triamcinolone Acetonide</paragraph>
                  <paragraph>GENERIC: Nystatin and Triamcinolone Acetonide</paragraph>
                  <paragraph>DOSAGE: CREAM</paragraph>
                  <paragraph>ADMINSTRATION: TOPICAL</paragraph>
                  <paragraph>NDC: 70518-1114-0</paragraph>
                  <paragraph>COLOR: yellow</paragraph>
                  <paragraph>PACKAGING: 30 g in 1 TUBE</paragraph>
                  <paragraph>OUTER PACKAGING: 1 in 1 CARTON</paragraph>
                  <paragraph>ACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>TRIAMCINOLONE ACETONIDE 1mg in 1g</item>
                     <item>NYSTATIN 100000[USP'U] in 1g</item>
                  </list>
                  <paragraph>INACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>POLYSORBATE 60</item>
                     <item>ALUMINUM HYDROXIDE</item>
                     <item>TITANIUM DIOXIDE</item>
                     <item>GLYCERYL MONOSTEARATE</item>
                     <item>SORBIC ACID</item>
                     <item>PROPYLENE GLYCOL</item>
                     <item>PETROLATUM</item>
                     <item>METHYLPARABEN</item>
                     <item>PROPYLPARABEN</item>
                     <item>SORBITOL</item>
                  </list>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_347aa0d3-ae82-ed7b-e063-6394a90ac68b"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250219"/>
               <component>
                  <observationMedia ID="img_347aa0d3-ae82-ed7b-e063-6394a90ac68b">
                     <text>MM1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Nystatin - Triamcinolone Acetonide 100000 -1g 1mg-1g_70518-1114-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>